JP2013522194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522194A5 JP2013522194A5 JP2012557033A JP2012557033A JP2013522194A5 JP 2013522194 A5 JP2013522194 A5 JP 2013522194A5 JP 2012557033 A JP2012557033 A JP 2012557033A JP 2012557033 A JP2012557033 A JP 2012557033A JP 2013522194 A5 JP2013522194 A5 JP 2013522194A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- item
- therapeutic agent
- dose
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 41
- 229940124597 therapeutic agent Drugs 0.000 claims description 41
- 239000000859 incretin Substances 0.000 claims description 22
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 108010011459 Exenatide Proteins 0.000 claims description 10
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 10
- 229960001519 exenatide Drugs 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000001771 impaired effect Effects 0.000 claims description 8
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 6
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 6
- 108010019598 Liraglutide Proteins 0.000 claims description 6
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 6
- 229960002701 liraglutide Drugs 0.000 claims description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 3
- -1 arubyglutide Chemical compound 0.000 claims description 3
- 230000000149 penetrating effect Effects 0.000 claims description 3
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 3
- 230000009747 swallowing Effects 0.000 claims description 3
- 108010048573 taspoglutide Proteins 0.000 claims description 3
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 claims description 3
- 229950007151 taspoglutide Drugs 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000000875 corresponding effect Effects 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 25
- 229940123208 Biguanide Drugs 0.000 description 7
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 5
- 102000003982 Parathyroid hormone Human genes 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 239000000199 parathyroid hormone Substances 0.000 description 4
- 229960001319 parathyroid hormone Drugs 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 208000024799 Thyroid disease Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33994110P | 2010-03-10 | 2010-03-10 | |
| US61/339,941 | 2010-03-10 | ||
| PCT/US2010/062073 WO2011112229A2 (en) | 2010-03-10 | 2010-12-23 | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015127337A Division JP6118371B2 (ja) | 2010-03-10 | 2015-06-25 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522194A JP2013522194A (ja) | 2013-06-13 |
| JP2013522194A5 true JP2013522194A5 (https=) | 2014-02-20 |
| JP5931757B2 JP5931757B2 (ja) | 2016-06-08 |
Family
ID=44564048
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557033A Active JP5931757B2 (ja) | 2010-03-10 | 2010-12-23 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2015127337A Active JP6118371B2 (ja) | 2010-03-10 | 2015-06-25 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2017059281A Withdrawn JP2017105854A (ja) | 2010-03-10 | 2017-03-24 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2018145276A Pending JP2018165281A (ja) | 2010-03-10 | 2018-08-01 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015127337A Active JP6118371B2 (ja) | 2010-03-10 | 2015-06-25 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2017059281A Withdrawn JP2017105854A (ja) | 2010-03-10 | 2017-03-24 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2018145276A Pending JP2018165281A (ja) | 2010-03-10 | 2018-08-01 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP3603624A1 (https=) |
| JP (4) | JP5931757B2 (https=) |
| CN (2) | CN105168174B (https=) |
| AU (3) | AU2010347732A1 (https=) |
| CA (1) | CA2792862C (https=) |
| WO (1) | WO2011112229A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2461818B1 (en) | 2009-08-03 | 2018-10-17 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| EP3603624A1 (en) | 2009-12-24 | 2020-02-05 | Rani Therapeutics, LLC | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8759284B2 (en) | 2009-12-24 | 2014-06-24 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| KR20190120430A (ko) * | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| EP2835147B1 (en) * | 2012-04-05 | 2019-11-13 | Hisamitsu Pharmaceutical Co., Inc. | Puncture device |
| US10264972B2 (en) | 2012-05-21 | 2019-04-23 | International Business Machines Corporation | Dispensing drugs from a companion diagnostic linked smart pill |
| SG11201706840WA (en) | 2015-03-31 | 2017-09-28 | Vhsquared Ltd | Peptide construct having a protease-cleavable linker |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| CN109152796A (zh) * | 2016-03-09 | 2019-01-04 | 因库博实验室有限责任公司 | 用于将活细胞递送至实体组织的方法和制品 |
| SG11201807402PA (en) | 2016-03-31 | 2018-09-27 | Vhsquared Ltd | Compositions |
| CN110035718B (zh) * | 2016-12-02 | 2021-04-06 | 克雷西奥生物科技有限公司 | 胃内滞留系统 |
| CN106725634B (zh) * | 2017-01-23 | 2024-01-16 | 天津医科大学总医院 | 肠道微生物采集胶囊 |
| US11207272B2 (en) * | 2017-05-17 | 2021-12-28 | Massachusetts Institute Of Technology | Tissue anchoring articles |
| CA3067021A1 (en) * | 2017-06-12 | 2018-12-20 | Incube Labs, Llc | Swallowable capsule, system and method for measuring gastric emptying parameters |
| CN107212846A (zh) * | 2017-08-07 | 2017-09-29 | 杨露 | 一种胃镜连接的胃酸检测装置 |
| US11547347B2 (en) | 2017-10-06 | 2023-01-10 | Massachusetts Institute Of Technology | Flexible piezoelectric devices for gastrointestinal motility sensing |
| JP7370974B2 (ja) * | 2017-11-07 | 2023-10-30 | ラニ セラピューティクス， エルエルシー | 嚥下可能薬物送達デバイスを使用する腸管組織への送達のための凝固因子調製物 |
| CN108619611B (zh) * | 2018-05-04 | 2020-11-06 | 哈尔滨工业大学深圳研究生院 | 一种具有多方向施药功能的肠道微型胶囊机器人 |
| GB201900780D0 (en) * | 2019-01-21 | 2019-03-06 | Vibrant Ltd | Device and method for delivering a flowable ingestible medicament into the gastrointestinal tract of a user |
| US12121688B2 (en) | 2019-02-01 | 2024-10-22 | Novo Nordisk A/S | Medical device with actuation mechanism |
| EP3917598B1 (en) | 2019-02-01 | 2025-10-29 | Massachusetts Institute of Technology | Systems for liquid injection |
| AU2020232610A1 (en) * | 2019-03-01 | 2021-09-23 | Rani Therapeutics, Llc | Propulsive drug delivery from a swallowable device into a patient's intestinal tract |
| KR102068616B1 (ko) * | 2019-03-15 | 2020-01-21 | (주)한국원자력 엔지니어링 | 장내 체류를 위한 내용물 운반체 |
| KR20220004148A (ko) * | 2019-05-03 | 2022-01-11 | 라니 테라퓨틱스, 엘엘씨 | 삼킬 수 있는 약물 전달 장치를 사용하여 장관 조직으로 전달하기 위한 응고인자 제제 |
| JP7539416B2 (ja) * | 2019-06-07 | 2024-08-23 | ノボ・ノルデイスク・エー／エス | 送達部材取り外しを有する摂取可能な装置 |
| US12559552B2 (en) | 2019-06-21 | 2026-02-24 | Sorriso Pharmaceuticals, Inc. | IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
| CA3144567A1 (en) | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
| CN114521124A (zh) * | 2019-08-26 | 2022-05-20 | Ajm Med-I-Caps有限公司 | 肠道诊断筛查装置及用于靶向胃肠道治疗的方法 |
| US11504519B2 (en) * | 2020-09-02 | 2022-11-22 | Fresenius Medical Care Holdings, Inc. | Releasable seal for catheter system |
| CN112717265B (zh) * | 2020-12-27 | 2023-04-07 | 河北医科大学第二医院 | 一种胃肠道肿瘤的靶点追踪装置及方法 |
| US20240149031A1 (en) * | 2021-03-05 | 2024-05-09 | Bitherapeutics Inc. | Oral drug delivery device |
| CN113769249B (zh) * | 2021-09-10 | 2023-08-04 | 安翰科技(武汉)股份有限公司 | 一种给药胶囊 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| JP2002542183A (ja) | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 成形可能な乾燥した医薬製剤 |
| US20050058701A1 (en) * | 2003-01-29 | 2005-03-17 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
| US20040267240A1 (en) * | 2003-01-29 | 2004-12-30 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
| CN1774239A (zh) * | 2003-01-29 | 2006-05-17 | 埃-皮尔制药公司 | 用于胃肠道的有效药物递送 |
| CN1953737A (zh) * | 2004-05-03 | 2007-04-25 | 埃-皮尔制药公司 | 胃肠道内的主动药物递送 |
| DE102004026615A1 (de) | 2004-06-01 | 2005-12-29 | Siemens Ag | Vorrichtung und Verfahren zur Freisetzung eines in das Körperinnere eines Patienten geführten therapeutischen Mittels |
| WO2006064502A2 (en) * | 2004-12-14 | 2006-06-22 | E-Pill Pharma, Ltd. | Local delivery of drugs or substances using electronic permeability increase |
| CN101107038A (zh) * | 2005-01-18 | 2008-01-16 | 皇家飞利浦电子股份有限公司 | 电控胶囊 |
| CN101511305B (zh) * | 2005-07-26 | 2012-05-30 | 梅纳赫姆·P·韦斯 | 伸展的体内胶囊 |
| US8021384B2 (en) * | 2005-07-26 | 2011-09-20 | Ram Weiss | Extending intrabody capsule |
| JP4402648B2 (ja) * | 2005-12-16 | 2010-01-20 | オリンパス株式会社 | 被検体内導入装置 |
| GB0603252D0 (en) * | 2006-02-17 | 2006-03-29 | Axcess Ltd | Dissolution aids for oral peptide delivery |
| CN101516314B (zh) * | 2006-09-18 | 2014-05-21 | 维伯兰特有限公司 | 胃肠胶囊 |
| WO2009041525A1 (ja) * | 2007-09-26 | 2009-04-02 | Olympus Medical Systems Corp. | 被検体内導入システム |
| EP2461818B1 (en) * | 2009-08-03 | 2018-10-17 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| CN102905753B (zh) * | 2009-12-24 | 2016-06-29 | 因卡伯实验室有限责任公司 | 可吞咽式药剂递送装置和药剂递送方法 |
| EP3603624A1 (en) * | 2009-12-24 | 2020-02-05 | Rani Therapeutics, LLC | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
-
2010
- 2010-12-23 EP EP19177552.7A patent/EP3603624A1/en not_active Withdrawn
- 2010-12-23 EP EP10847622.7A patent/EP2544668B1/en not_active Revoked
- 2010-12-23 JP JP2012557033A patent/JP5931757B2/ja active Active
- 2010-12-23 CN CN201510345861.8A patent/CN105168174B/zh active Active
- 2010-12-23 CN CN201080066694.9A patent/CN103025319B/zh active Active
- 2010-12-23 AU AU2010347732A patent/AU2010347732A1/en not_active Abandoned
- 2010-12-23 CA CA2792862A patent/CA2792862C/en active Active
- 2010-12-23 WO PCT/US2010/062073 patent/WO2011112229A2/en not_active Ceased
-
2015
- 2015-06-25 JP JP2015127337A patent/JP6118371B2/ja active Active
-
2016
- 2016-10-28 AU AU2016250444A patent/AU2016250444B2/en active Active
-
2017
- 2017-03-24 JP JP2017059281A patent/JP2017105854A/ja not_active Withdrawn
-
2018
- 2018-08-01 JP JP2018145276A patent/JP2018165281A/ja active Pending
-
2019
- 2019-03-13 AU AU2019201724A patent/AU2019201724B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522194A5 (https=) | ||
| US11376405B2 (en) | Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device | |
| JP2020058871A5 (https=) | ||
| AU2019201724B2 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
| FI3756657T3 (fi) | Nieltävä lääkkeenantolaite | |
| RU2547990C2 (ru) | Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства | |
| JP2008520544A5 (ja) | 癌関連疲労の治療または予防のための医薬の製造への使用方法 | |
| JP2013515576A5 (https=) | ||
| KR101900520B1 (ko) | 복합 조성물 | |
| JP2019517542A5 (https=) | ||
| JP2014524480A5 (https=) | ||
| IL307966A (en) | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug | |
| JP2002544231A5 (https=) | ||
| JP2004530721A5 (https=) | ||
| WO2011041311A2 (en) | Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods | |
| US20170189363A1 (en) | Gastric acid modulators for oral delivery of peptides and proteins | |
| WO2024167986A2 (en) | Programmable drug-device microneedle system for the treament of diabetes, obesity, and associated conditions | |
| CN111770748A (zh) | 药物递送系统 | |
| EP4090351B1 (en) | Dosing regimen of glp-1 | |
| KR20250117456A (ko) | 소분자 항바이러스제의 고체 투여 형태 및 그의 용도 | |
| Croasdell | European Association for the Study of Diabetes (EASD)-53rd Annual Meeting. Lisbon, Portugal-September 11-15, 2017 | |
| HK1245156A1 (en) | Rapid establishment and/or termination of substantial steady-state drug delivery |